Rangam ยท 4 days ago
RCI-PFE-2711 Scientist (Immunology/in vitro/CRISPRi/CRISPRa)- Cambridge, MA
Rangam is seeking a scientist to join their Systems Immunology Lab. The successful candidate will be responsible for generating massive single-cell perturbational data using functional genomics and single cell transcriptomics technologies in collaboration with a small team.
Responsibilities
Generate custom lentiviral libraries and maintain extensive cell cultures. Generate edited pools of cells via lentiviral transduction and arrayed electroporation
Develop, modify, and customize such procedures as needed to succeed in specific cell lines and types, and at large scale. Generate single-cell data via several commercial workflows, including from 10x Genomics
Qualification
Required
Bachelors or Masters + 3 years of experience in Biology, Immunology, or a related field
3+ years of hands-on experience with standard cell culture techniques including primary immune cells handling and isolation, maintenance of cell lines and in vitro stimulation of primary immune cells
Experience with standard molecular biology techniques including lentivirus infection, qPCR, western blot, and flow cytometry
Preferred
Direct experience in pooled cell screening of immune cells using CRISPRi, CRISPRa, and other methods of in vitro gene editing
Company
Rangam
Rangam is a global, innovative, Total Talent management firm with the mission of accelerating meaningful employment for everyone!โ We are a minority-, woman-, and disability-owned firm with over 25 years of experience promoting sustainable and inclusive talent programs within our communities and employers.
H1B Sponsorship
Rangam has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (10)
2024 (2)
2023 (4)
2022 (5)
2021 (4)
2020 (9)
Funding
Current Stage
Late StageCompany data provided by crunchbase